The 4th International Electronic Conference on Cancers (IECC 2024)
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: 31 December 2024 | Viewed by 991
Special Issue Editors
2. Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology-Hellas, 45110 Ioannina, Greece
Interests: cancer epigenetics; cancer stem cells; breast cancer; tumor heterogeneity; epigenetic therapies
Special Issues, Collections and Topics in MDPI journals
Interests: neurooncology; CNS malignancies; glioma; lymphoma; brain metastasis; radiation oncology; surgical oncology; neuroimaging; clinical trials; drug delivery; boron neutron capture therapy (BNCT)
Interests: neurosurgery; CyberKnife; radiosurgery
Special Issues, Collections and Topics in MDPI journals
Interests: immunology; protein crystallography; medicinal chemistry; cellular and molecular biology; extensive translational research; clinical trials; vaccines; drugs; healthy ageing; chronic diseases; inflammation
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
It is a great pleasure to welcome you to the 4th International Electronic Conference on Cancers (IECC 2024), which will be held from 6–8 March 2024. This electronic conference will be held online at sciforum.net, a platform developed and maintained by MDPI for hosting conferences. It will enable scientists from all over the world to present their latest research in Cancers, receive direct feedback, and engage in discussions with the wider scientific community.
In recent years, we have witnessed remarkable breakthroughs in basic cancer research, where discoveries regarding of the composition of the genetic and epigenetic tumors, as well as in the tumor microenvironment, have provided valuable insights into the molecular mechanisms underlying cancer initiation, progression, and therapeutic response. This newfound knowledge has laid the groundwork for novel treatment strategies and personalized approaches that hold the potential to revolutionize cancer care. This conference aspires to connect clinicians and scientists with diverse expertise and perspectives in cancer research so that they may interact, exchange ideas and form new collaborations that could lead to new advancements in scientific understanding and ultimately impact patient outcomes.
This year’s conference is dedicated to the following sessions:
SESSION A. Brain Metastases
SESSION B. Cancer Biomarkers
SESSION C. Cancer Immunology and Immunotherapy
SESSION D. Tumor Microenvironment
SESSION E. Molecular Cancer Biology
SESSION F. Cancer Epidemiology and Prevention
SESSION G. Cancer Therapy
SESSION H. Cancer Pathophysiology
The IECC 2024 will be an online-only proceeding, which enables researchers to participate from all over the world with no requirement for travel or related expenditures. An electronic conference provides a platform for rapid and direct exchanges regarding the latest research findings and novel ideas.
We are committed to equality and inclusion principles. Therefore, we ask authors to ensure that the papers and presentations are highly accessible to the wider and more diverse scientific community. We encourage submissions from scientists at all career stages and backgrounds and aim for an equal gender balance.
Participants in this conference are cordially invited to contribute a full manuscript to this Special Issue published in Cancers (ISSN: 2072-6694, IF 5.2), with a 20% discount on the publication fee. Please note that no other discounts are applicable. All submitted papers will undergo MDPI’s standard peer-review procedure. The abstracts should be cited and noted on the first page of the paper. We look forward to receiving your contributions to this scientific event and would like to thank you in advance for your active support.
Dr. Angeliki Magklara
Dr. Shinji Kawabata
Dr. Alfredo Conti
Prof. Dr. Vasso Apostolopoulos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
